Shots:

• AveXis- a Novartis company purchases gene therapy manufacturing unit in Longmont- an addition to Durham facility of $115M investment- offering positions for 150 employees previously working at the site and further expansion of new jobs in H2’19
• The focus of purchase is to expand the production unit leading to the preparation of Zolgensma’s (onasemnogene abeparvovec-xioi; AVXS-101) launch and become the largest of four state-of-the-art sites in developing therapies for rare genetic diseases including SMA
• The fourth location in the US site consists of 700-000 square-feet of space for biologic drug manufacturing- laboratories- warehousing and utilities with initial practices of testing therapies and hiring staff. Zolgensma is a gene therapy targeted as one-time infusion for SMA Type 1 with its BLA accepted by FDA  

Ref: Novartis | Image: Savsu